Recent advances in immunology have underscored the pivotal role of the transcription factor RORγt in orchestrating the differentiation of Th17 cells and the consequent production of proinflammatory ...

NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the ...

NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the ...

Please provide your email address to receive an email when new articles are posted on . In a phase 2a trial, monlunabant, a novel oral cannabinoid receptor 1 inverse agonist, was tied to weight loss ...

NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release results ...

There has been growing interest in developing novel cannabinoid CB1 receptor inverse agonists to treat obesity and its metabolic comorbidities. At the European Association for the Study of Diabetes ...

OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced the publication in Nature ...

Monlunabant, a novel cannabinoid receptor 1 (CB1R) inverse agonist, led to significant weight loss compared with placebo in patients with obesity and metabolic syndrome over 16 weeks; however, ...

CRB-913 was safe and well-tolerated across all doses studied Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants A placebo-adjusted mean weight loss of ...

CRB-913 is a member of a new class of peripherally restricted CB1 inverse agonists designed to have reduced brain penetration. Pre-clinical models have shown CRB-913 to be 15-fold less brain penetrant ...